Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kalvista Pharmaceuticals Inc

12.96
-0.1300-0.99%
Post-market: 13.000.0400+0.31%19:28 EDT
Volume:772.13K
Turnover:10.05M
Market Cap:644.31M
PE:-3.48
High:13.37
Open:13.00
Low:12.84
Close:13.09
Loading ...

KalVista says FDA will not meet PDUFA goal date for Sebetralstat NDA

TIPRANKS
·
Yesterday

KalVista Pharmaceuticals Announces Delay in FDA Decision on Sebetralstat NDA for Hereditary Angioedema Due to Agency Resource Constraints

Reuters
·
Yesterday

Kalvista Pharmaceuticals Inc - FDA Anticipates Decision Within Four Weeks

THOMSON REUTERS
·
Yesterday

Kalvista Pharmaceuticals Announces FDA Will Not Meet Pdufa Goal Date for Sebetralstat Nda for Hereditary Angioedema Due to FDA Resource Constraints

THOMSON REUTERS
·
Yesterday

CEO Benjamin L. Palleiko Reports Disposal of KalVista Pharmaceuticals Common Shares

Reuters
·
11 Jun

KalVista Pharmaceuticals Announces Inducement Grants for New Employees Under Nasdaq Rule 5635(c)(4)

Reuters
·
04 Jun

Kalvista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Jun

KalVista Pharmaceuticals (KALV) Gets a Buy from JonesTrading

TIPRANKS
·
03 Jun

KalVista Pharmaceuticals to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Reuters
·
29 May

Kalvista Pharmaceuticals Inc. Chief Development Officer Christopher Yea Reports Disposal of Common Shares

Reuters
·
28 May

Benjamin L. Palleiko, CEO, Reports Disposal of KalVista Pharmaceuticals Inc. Common Shares

Reuters
·
24 May

Kalvista Pharmaceuticals' Chief Medical Officer Paul K. Audhya Reports Disposal of Common Shares

Reuters
·
24 May

Kalvista Pharmaceuticals Inc. Unveils Presentation on Transformative Oral Treatment for HAE

Reuters
·
14 May

Kalvista Pharmaceuticals Inc. Announces Resignation of Chief Operating Officer Jebediah T. Ledell

Reuters
·
13 May

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
02 May

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

Business Wire
·
30 Apr

KalVista Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham

Dow Jones
·
08 Apr

KalVista Signs Deal With Kaken to Commercialize Hereditary Angioedema Treatment in Japan

MT Newswires Live
·
08 Apr

BRIEF-Kalvista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical To Commercialize Sebetralstat For HAE In Japan

Reuters
·
08 Apr

Kalvista Pharmaceuticals Inc - up to $24 Mln in Upfront and Milestone Payments, Plus Royalties

THOMSON REUTERS
·
08 Apr